Should Researchers Tell Participants About Unexpected Findings?

You Found Something Unexpected. Should You Tell the Participant?

A researcher reviewing an MRI notices an abnormal-looking area unrelated to the study. A genomic analysis unexpectedly reveals a variant that might have health implications. A physiological measurement produces a value that looks concerning even though it is not part of the research question.

Once researchers become aware of potentially important information about an individual participant, silence can feel uncomfortable. But disclosure is not automatically the safer or more ethical choice. Research findings may be preliminary, technically uncertain, outside the researcher's expertise, or generated using procedures that were never intended for clinical diagnosis.

The real question is therefore not simply, “Should I tell them?” It is whether the information is reliable and important enough to justify disclosure, whether disclosure is consistent with the participant's preferences and the approved research plan, and how it can be communicated without turning an uncertain observation into an apparent diagnosis.

Some Unexpected Findings Should Be Offered, but Not Every Finding Should Be Disclosed

Disclosure Is an Ethical Decision, Not an Automatic Consequence of Discovery

Discovery and disclosure are separate decisions

Finding information about a participant does not by itself establish that the participant should receive it. This distinction is fundamental to the ethical management of incidental findings in research.

A researcher may notice something potentially significant and have a responsibility to respond without yet having enough evidence to disclose the finding directly. Appropriate response could initially mean documenting the observation, consulting the study's protocol, obtaining specialist review, confirming the result, or consulting the ethics committee or IRB.

Keeping these steps separate prevents a preliminary research observation from acquiring more certainty simply because someone tells the participant about it.

Why not simply disclose everything?

More information is not invariably better information. Research procedures are designed primarily to answer research questions, and their outputs may not meet the standards expected of clinical diagnosis. Unexpected observations can include technical artifacts, false positives, uncertain variants, measurements with unclear significance, or findings that specialists would interpret differently.

Disclosure can therefore cause harm as well as benefit. Participants may experience anxiety, undergo unnecessary diagnostic procedures, incur financial costs, misunderstand their risk, or make important decisions based on information that later proves incorrect.

This is one reason established frameworks for returning individual research results and incidental findings commonly consider analytic validity, significance, actionability, participant consent, and expected benefit rather than recommending unrestricted disclosure.

Why not simply withhold everything outside the research question?

The opposite rule is also difficult to defend. Some unexpected findings can identify serious and preventable threats to a participant's health. A rigid policy of silence could leave a participant unaware of information that might permit effective treatment, surveillance, prevention, or another meaningful response.

NHGRI notes continuing debate about exactly which genomic research findings should be returned but reports that many genomic researchers consider medically actionable incidental findings a minimum category for return after appropriate informed consent. The broader literature has similarly developed approaches in which some findings should be offered, others may be offered, and findings unlikely to provide net benefit generally should not be returned.

Disclosure usually requires confidence that the finding is real

Analytic validity concerns whether the measurement or analysis accurately identifies what it claims to identify. This is different from asking whether the finding predicts a disease or whether something useful can be done about it.

If a result has a substantial possibility of being technically wrong, disclosure may expose a participant to the harms of misinformation. Some return frameworks therefore require independent confirmation or another appropriate validation process before individual findings are communicated.

Exactly what confirmation requires depends on the research modality and applicable rules. Researchers should not assume that an exploratory research assay, imaging observation, algorithmic classification, or preliminary analysis can simply be translated into a clinical conclusion.

The finding's significance matters

A technically accurate finding can still be too trivial or poorly understood to justify disclosure. Researchers should ask what the information plausibly means for the participant.

Potentially life-threatening conditions present a different ethical case from minor abnormalities with no expected consequences. Likewise, a well-established disease association differs from an observation whose relationship to future health remains highly speculative.

This is why the more difficult question of what makes an incidental finding important enough to return cannot be answered merely by establishing that the observation is technically correct.

Actionability strengthens the case for disclosure

A finding is often described as clinically actionable when knowing it can lead to an intervention that may prevent disease, reduce risk, alter treatment, enable surveillance, or otherwise improve management. Actionability can substantially strengthen the justification for return because disclosure gives the participant something useful to do with the information.

Yet actionability itself is not perfectly binary. An intervention might reduce risk without eliminating it. Surveillance may be available even when prevention is not. Some information may also have reproductive or personal utility that participants regard as important.

Accordingly, whether an incidental finding must be clinically actionable before it should be returned requires a more nuanced analysis than “actionable equals disclose.”

Participant preferences matter too

Disclosure is closely connected to respect for autonomy. Participants may value access to important information generated about them, but they may also have reasons for declining certain information. Genetic findings can be particularly consequential because they may imply future disease risk, affect relatives, or reveal information for which no treatment exists.

The consent process should therefore explain, where reasonably foreseeable, what categories of individual or incidental findings may arise, whether researchers plan to offer them, and what choices participants have. The Presidential Commission emphasized anticipating incidental and secondary findings and communicating the management plan through the research protocol and informed-consent process.

The separate question of whether participants should choose which findings they receive becomes particularly important when findings differ substantially in certainty, seriousness, and actionability.

Consent does not make unreliable information reliable

A participant might say, “Tell me absolutely everything you find.” That preference matters, but it does not necessarily require researchers to return every raw observation or speculative interpretation.

Consent to receive findings addresses whether the participant wants information. It does not establish the scientific validity, clinical significance, or responsible interpretability of that information. A research team may therefore have good reasons not to return a finding even when the participant has expressed a broad desire for results.

Disclosure should match the researcher's expertise

A researcher who identifies a possible abnormality may not be the right person to explain its medical implications. Incidental findings are especially likely to fall outside the research team's expertise precisely because they are outside the study's aims.

Responsible disclosure may therefore require a physician, radiologist, genetic counselor, psychologist, or another appropriately qualified professional. Some guidance for population studies specifically recommends procedures for communicating material findings through a health professional.

This does not necessarily mean that every finding requires a clinical consultation. It means the communication pathway should reflect the nature and potential consequences of the information. The question of who should explain an incidental finding should ideally be resolved before a difficult case arises.

Urgency can change the process

Most incidental findings permit time for assessment, consultation, and confirmation. Occasionally, however, an observation may suggest an immediate or serious threat to a participant's health or safety.

In those circumstances, delay itself may become ethically consequential. Researchers should follow the approved safety and escalation procedures applicable to the study rather than treating an urgent risk as an ordinary return-of-results decision. How researchers should respond when a finding may affect a participant's health or safety therefore warrants separate treatment.

An Unexpected Finding Appears on a Research Scan

If specialist review instead showed that the apparent abnormality was a routine artifact, disclosure could provide no meaningful benefit and might cause needless anxiety. The ethical difference lies not simply in whether the researcher saw something unusual, but in what responsible evaluation showed that observation to mean.

Common Mistakes About Disclosing Unexpected Findings

Ask Whether Disclosure Helps the Participant More Than It Harms

Do not reduce the decision to “tell” versus “do not tell.” First determine whether you have information reliable enough to support a responsible disclosure. Then consider what the information means, what the participant can reasonably do with it, what the participant wanted, and what harms might follow from either disclosure or nondisclosure.

Most importantly, decide as much of this as possible before data collection begins. A predefined policy will not eliminate difficult judgment calls, but it is considerably better than inventing a disclosure standard after learning something alarming about a particular participant.

Before Telling a Participant About an Unexpected Finding

Questions About Returning Unexpected Findings

Do Not Confuse Transparency With Returning Everything

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.